Emulsified cell walls of Mycobacterium bovis (BCG) were immunotherapeutically at least as active as living BCG in prolonging survival of guinea pigs with established dermal tumors and microscopic lymph node and visceral metastases.
Living Mycobacterium bovis, strain BCG, has been administered intradermally (i.d.) (5, 6, 8, 9) or systemically (1, 2, 4) to cancer patients in attempts to eradicate localized and/or disseminated tumors remaining or recurring after other forms of treatment. One possible undesirable effect of administering living BCG is systemic BCG infection. Nonviable, but immunotherapeutically active, mycobacterial preparations might be useful clinically. Living BCG has been used to treat guinea pigs with established dermal tumors and artificial hematogenous metastases initiated by intravenous injection of tumor cells (3) . The purpose of this study was to compare the efficacy of BCG cell walls (CW) (11) 
